[{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus DMCC","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Factor IIa","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Laboratori Derivati Organici \/ Cerus DMCC","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori Derivati Organici \/ Cerus DMCC"}]

Find Clinical Drug Pipeline Developments & Deals by Laboratori Derivati Organici

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 29, 2020

                          Lead Product(s) : Heparin Sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Cerus DMCC

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank